MICHAEL ROBERTS, PA-C
Physician Assistant at Piedmont Blvd, Rock Hill, SC

2013019, Aug 1, 2013

Jan 30, 2013

13/754001

Chelsea Therapeutics, Inc. - Charlotte NC, US
William Schwieterman - Mobile AL, US
Cameron Szakacs - Charlotte NC, US
Gerry Rowse - Waxhaw NC, US
Christopher Cioffi - Charlotte NC, US
Michael J. Roberts - Charlotte NC, US

Chelsea Therapeutics, Inc. - Charlotte NC

A61K 31/198, A61K 45/06

514567

The present invention provides methods and systems for reducing falls in patients that are recurrent fallers. Specifically, the compositions, systems, and methods can relate to Parkinson's disease patients, particularly such patients that are suffering from neurogenic orthostatic hypotension. The compositions, systems, and methods comprise the use of droxidopa, optionally in combination with a further active agent. Administration of droxidopa has been found to reduce the mean number of falls per patient per week, as well as provide improvements in the patient's Hoehn and Yahr rating scale score, which is indicative of improvements in postural stability, and provide improvements in the patient's Unified Parkinson's disease Rating Scale score, which is indicative of improvements in the severity of motor and/or non-motor symptoms of Parkinson's disease.

8071678, Dec 6, 2011

Oct 11, 2010

12/902072

Michael J. Roberts - Charlotte NC, US
Zhihao Fang - Madison AL, US

Nektar Therapeutics - San Francisco CA

C08G 63/50

525 541, 525 542, 525398, 525400, 525437, 525535, 525539, 514 22, 514 23, 514402, 514404, 514408

The invention provides reagents and methods for conjugating a polymer specifically to the α-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the α-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.

8383681, Feb 26, 2013

May 7, 2008

12/116560

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

Chelsea Therapeutics, Inc. - Charlotte NC

A61K 31/195, A61K 31/19, A61K 31/135

514567, 514653

The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).

8372422, Feb 12, 2013

Oct 6, 2010

12/899521

Antoni Kozlowski - Huntsville AL, US
Michael J. Roberts - Charlotte NC, US

Nektar Therapeutics - San Francisco CA

A61F 2/00, A61K 31/74, A61K 31/00, A61K 47/48, A61K 31/79

424423, 424 7818, 424 783, 424 7817, 424 7824

Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.

2011025, Oct 27, 2011

Jul 1, 2011

13/174827

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

B65D 69/00

206570

The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.

2011015, Jun 23, 2011

Feb 25, 2011

13/035338

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

A61K 31/519, A61P 11/06, A61P 19/02, A61P 29/00, A61P 35/00, A61P 17/06, A61P 27/02, A61P 9/10, A61P 35/02

514249, 5142651

The present invention is directed to antifolate compounds having the structurewherein: